New evidence continues to emerge to support the idea that deficiencies in APP trafficking and clearance of Aβ peptides is the initiating event of AD pathogenic processes (Tan and Gleeson, 2019; Zhao et al., 2020). The gene discussed is APP; the disease is Alzheimer disease.